SiO2 Medical Products filed an SEC Form D this week revealing that the company pulled in nearly $50 million in a debt offering. The Auburn, Ala.-based company reeled in a total of $48 million, according to the filing. SiO2 is seeking $60 million in the debt offering, with $12 million of the offering remaining to […]
BD drug-dispensing cabinets vulnerable to cyberattack
The U.S. Department of Homeland Security said yesterday that certain Becton Dickinson Pyxis medication-dispensing cabinets are vulnerable to unauthorized users within a local hospital network. The Franklin Lakes, N.J.-based company said it reported the vulnerability to federal officials. The weakness would have allowed someone with the expired credentials to access patient data and medications. The […]
Enable Injections inks deal with Genentech
Enable Injections said yesterday that it entered a developmental partnership with Genentech for the Enable enFuse device. Cincinnati-based Enable’s enFuse is an on-body drug delivery platform containing a drug transfer system compatible with syringes and vial containers. Currently, the enFuse is being developed for subcutaneous delivery of large volumes potentially rising to 50 mL. The […]
FDA wants more on new manufacturing process from Clearside Biomedical
Clearside Biomedical (NSDQ:CLSD) said today that the FDA ordered the company to provide stability data on its new manufacturing process for triamcinolone acetonide suspension, pushing the timeline on the agency’s decision into next year. Alpharetta, Ga.-based Clearside’s Xipere device is a suprachoroidal injection designed for the treatment of macular edema associated with uveitis. Clearside said the […]
Teva launches generic EpiPen Jr.
Teva (NYSE:TEVA) today announced that its FDA-approved generic EpiPen Jr. auto-injector is available in the U.S. The device wholesales to most retail pharmacies in packs of two for $300, or $150 per pen. Teva’s product is less than half the cost of Mylan’s non-generic EpiPen Jr., which lists at $643.89 per two-pack at Drugs.com. Get the full story at […]
Insulet touts full market launch of mobile apps for Omnipod Dash
Insulet (NSDQ:PODD) touted the full market launch of the Omnipod Display and Omnipod View apps for people using the company’s Omnipod Dash system. The Display app enables users to display data from their Personal Diabetes Manager device onto their smartphones. The View app gives caregivers and family members the option to remotely monitor Omnipod Dash system […]
On mixed Q2 results, Glaukos announces Avedro buy
Glaukos (NYSE:GKOS) posted its second-quarter financial results this week and reported that it plans to acquire Avedro in an effort to build out its corneal health franchise. Avedro develops single-use drug formulations designed to strengthen corneal tissue and stop the progression of a degenerative corneal ectatic disease known as keratoconus. According to the Mass.-based company, the total U.S. […]
Pfizer to absorb Mylan in off-patent drug spinout
Pfizer (NYSE:PFE) plans to absorb Mylan (NSDQ:MYL) as part of the spinout of its Upjohn off-patent drugs business in an all-stock deal. The deal, structured to avoid taxes on any gains from the spinout, would see each Mylan share converted into a share of the as-yet-unnamed new company. Pfizer stockholders would then own 57% of the new firm, […]
Frequency Therapeutics inks $625m deal with Astellas, adds $62m Series C
Frequency Therapeutics said today that it raised a $62.0 million Series C round for the hearing loss drug it’s developing and inked a development and overseas distribution deal with Astellas Pharma that’s worth $625 million. Woburn, Mass.-based Frequency drew a $42 million Series B early this year; including the financing announced today, a $32 million Series A and seed […]
Avoset to develop infusion pump with unnamed pharma giant
Avoset Health said this week that it plans to develop a connected infusion pump with an unnamed pharmaceutical company. The product is set to debut in early 2021. The company touted that its technology allows physicians and pharmacists to track when patients receive infusions, how much drug was infused and which patients need additional intervention. Get […]
NovaBay raises $2.4m
NovaBay Pharmaceuticals (NYSE:NBY) said this week that it raised $2.4 million in an offering that included three investors. The Emeryville, Calif.-based company has developed products for the eye care market, including a prescription for managing hygiene of the eyelids and lashes. Get the full story at our sister site, Drug Delivery Business News.
- 1
- 2
- 3
- …
- 173
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube